Any question about our company, a partnership, or job opportunities?
Please complete our contact form and we will get in touch ASAP
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested.
Utilizing whole-exome sequencing data for in-human AI drug discovery
Gero.ai identifies rare mutations sufficiently affecting health from real-world big clinical and genetic (WES) and molecular data and then suggests druggable targets and drugs (mimicking or inhibiting) the effect of mutation to treat the disease.
We are able to aggregate the effects of multiple rare mutations on the level of biological processes and pathways and give you multiple choices of interventions with the required effect.
Aging is a natural part and the "last mile" of a human development program, and Gero pioneer ways to understand, measure, and, ultimately, control its progression.
Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts ultimate limit of human lifespan
T. Pyrkov, K. Avchaciov, A. Tarkhov, L. Menshikov, A. Gudkov, P. Fedichev
We introduce a novel blood-based biomarker of aging, the dynamic organism state indicator (DOSI). DOSI is associated with frailty and predicts the prospective incidence of age-related diseases and death. Age-related broadening of DOSI distribution is associated with a progressive loss of physiological resilience. Extrapolation suggests that recovery time would diverge at a critical point of 120 – 150 years of age and signifies a fundamental or absolute limit of human lifespan.